Cargando…
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
OBJECTIVE: Randomized controlled trials have shown kidney-protective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546274/ https://www.ncbi.nlm.nih.gov/pubmed/34593566 http://dx.doi.org/10.2337/dc21-1081 |
_version_ | 1784590159886417920 |
---|---|
author | Nagasu, Hajime Yano, Yuichiro Kanegae, Hiroshi Heerspink, Hiddo J.L. Nangaku, Masaomi Hirakawa, Yosuke Sugawara, Yuka Nakagawa, Naoki Tani, Yuji Wada, Jun Sugiyama, Hitoshi Tsuruya, Kazuhiko Nakano, Toshiaki Maruyama, Shoichi Wada, Takashi Yamagata, Kunihiro Narita, Ichiei Tamura, Kouichi Yanagita, Motoko Terada, Yoshio Shigematsu, Takashi Sofue, Tadashi Ito, Takafumi Okada, Hirokazu Nakashima, Naoki Kataoka, Hiromi Ohe, Kazuhiko Okada, Mihoko Itano, Seiji Nishiyama, Akira Kanda, Eiichiro Ueki, Kohjiro Kashihara, Naoki |
author_facet | Nagasu, Hajime Yano, Yuichiro Kanegae, Hiroshi Heerspink, Hiddo J.L. Nangaku, Masaomi Hirakawa, Yosuke Sugawara, Yuka Nakagawa, Naoki Tani, Yuji Wada, Jun Sugiyama, Hitoshi Tsuruya, Kazuhiko Nakano, Toshiaki Maruyama, Shoichi Wada, Takashi Yamagata, Kunihiro Narita, Ichiei Tamura, Kouichi Yanagita, Motoko Terada, Yoshio Shigematsu, Takashi Sofue, Tadashi Ito, Takafumi Okada, Hirokazu Nakashima, Naoki Kataoka, Hiromi Ohe, Kazuhiko Okada, Mihoko Itano, Seiji Nishiyama, Akira Kanda, Eiichiro Ueki, Kohjiro Kashihara, Naoki |
author_sort | Nagasu, Hajime |
collection | PubMed |
description | OBJECTIVE: Randomized controlled trials have shown kidney-protective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown. RESEARCH DESIGN AND METHODS: Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease. RESULTS: At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL/min per 1.73 m(2), and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL/min/1.73 m(2) per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26–0.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (P(heterogeneity) ≥ 0.35). CONCLUSIONS: The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria. |
format | Online Article Text |
id | pubmed-8546274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-85462742021-11-02 Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database Nagasu, Hajime Yano, Yuichiro Kanegae, Hiroshi Heerspink, Hiddo J.L. Nangaku, Masaomi Hirakawa, Yosuke Sugawara, Yuka Nakagawa, Naoki Tani, Yuji Wada, Jun Sugiyama, Hitoshi Tsuruya, Kazuhiko Nakano, Toshiaki Maruyama, Shoichi Wada, Takashi Yamagata, Kunihiro Narita, Ichiei Tamura, Kouichi Yanagita, Motoko Terada, Yoshio Shigematsu, Takashi Sofue, Tadashi Ito, Takafumi Okada, Hirokazu Nakashima, Naoki Kataoka, Hiromi Ohe, Kazuhiko Okada, Mihoko Itano, Seiji Nishiyama, Akira Kanda, Eiichiro Ueki, Kohjiro Kashihara, Naoki Diabetes Care Emerging Therapies: Drugs and Regimens OBJECTIVE: Randomized controlled trials have shown kidney-protective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown. RESEARCH DESIGN AND METHODS: Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease. RESULTS: At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL/min per 1.73 m(2), and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL/min/1.73 m(2) per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26–0.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (P(heterogeneity) ≥ 0.35). CONCLUSIONS: The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria. American Diabetes Association 2021-11 2021-10-18 /pmc/articles/PMC8546274/ /pubmed/34593566 http://dx.doi.org/10.2337/dc21-1081 Text en © 2021 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license. |
spellingShingle | Emerging Therapies: Drugs and Regimens Nagasu, Hajime Yano, Yuichiro Kanegae, Hiroshi Heerspink, Hiddo J.L. Nangaku, Masaomi Hirakawa, Yosuke Sugawara, Yuka Nakagawa, Naoki Tani, Yuji Wada, Jun Sugiyama, Hitoshi Tsuruya, Kazuhiko Nakano, Toshiaki Maruyama, Shoichi Wada, Takashi Yamagata, Kunihiro Narita, Ichiei Tamura, Kouichi Yanagita, Motoko Terada, Yoshio Shigematsu, Takashi Sofue, Tadashi Ito, Takafumi Okada, Hirokazu Nakashima, Naoki Kataoka, Hiromi Ohe, Kazuhiko Okada, Mihoko Itano, Seiji Nishiyama, Akira Kanda, Eiichiro Ueki, Kohjiro Kashihara, Naoki Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database |
title | Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database |
title_full | Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database |
title_fullStr | Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database |
title_full_unstemmed | Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database |
title_short | Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database |
title_sort | kidney outcomes associated with sglt2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the japan chronic kidney disease database |
topic | Emerging Therapies: Drugs and Regimens |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546274/ https://www.ncbi.nlm.nih.gov/pubmed/34593566 http://dx.doi.org/10.2337/dc21-1081 |
work_keys_str_mv | AT nagasuhajime kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT yanoyuichiro kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT kanegaehiroshi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT heerspinkhiddojl kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT nangakumasaomi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT hirakawayosuke kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT sugawarayuka kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT nakagawanaoki kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT taniyuji kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT wadajun kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT sugiyamahitoshi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT tsuruyakazuhiko kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT nakanotoshiaki kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT maruyamashoichi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT wadatakashi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT yamagatakunihiro kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT naritaichiei kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT tamurakouichi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT yanagitamotoko kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT teradayoshio kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT shigematsutakashi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT sofuetadashi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT itotakafumi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT okadahirokazu kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT nakashimanaoki kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT kataokahiromi kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT ohekazuhiko kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT okadamihoko kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT itanoseiji kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT nishiyamaakira kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT kandaeiichiro kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT uekikohjiro kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase AT kashiharanaoki kidneyoutcomesassociatedwithsglt2inhibitorsversusotherglucoseloweringdrugsinrealworldclinicalpracticethejapanchronickidneydiseasedatabase |